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Dose de-escalation to the 
normal larynx using conformal 
radiotherapy reduces toxicity while 
maintaining oncologic outcome for 
T1/T2 glottic cancer
Jun Won Kim1, Hyung Kwon Byeon2, Hong-Shik Choi2 & Ik Jae Lee1
We evaluated the efficacy of dose de-escalation to the normal larynx using conformal radiotherapy 
(CRT) for T1/T2 glottic cancer. For conventional RT (2DRT, n = 38), the laryngeal box received a median 
equivalent dose in 2 Gy fractions (EQD2) of 66 Gy. For CRT (n = 42; 3D-CRT, 20; intensity-modulated 
RT, 22), clinical target volume (CTV)1 (gross tumor with a 3-mm margin) and CTV2 (laryngeal box) 
received median EQD2s of 66.6 Gy and 52.2 Gy, respectively. With a 71-month median follow-up, five-
year local control and overall survival rates for 2DRT vs. CRT were 88.1% vs. 95.1% (p = 0.405) and 
94.7% vs. 90.7% (p = 0.102), respectively. Grade 2 and 3 pharyngitis rates were 52.6% and 5.3% for 
2DRT vs. 35.7% and 2.4% for CRT (p = 0.121). Grade 2 and 3 dermatitis rates were 42.1% and 2.6% for 
2DRT vs. 35.7% and 0% for CRT (p = 0.013). The maximum phonation time increased from 12.1 ± 7.1 
to 14.0 ± 6.6 seconds after 2DRT (p = 0.375) and from 12.0 ± 5.5 to 13.8 ± 10.1 seconds after CRT 
(p = 0.313). Fundamental frequency decreased from 150.6 ± 40.3 to 121.9 ± 30.2 Hz after 2DRT 
(p = 0.039) and from 138.5 ± 31.9 to 126.1 ± 23.7 Hz after CRT (p = 0.058). CRT can effectively de-
escalate the normal larynx dose while maintaining oncologic outcome and voice quality.
Approximately two-thirds of laryngeal cancers arise in the glottic region, and 80–85% of those patients present 
with early–stage (T1–T2) disease1. Radiation therapy (RT) and endolaryngeal surgery are standard treatments 
for early-stage glottic cancers2. Intensity-modulated radiotherapy (IMRT) has been widely used to treat head and 
neck cancers and has yielded significant benefits in terms of reducing toxicity and improving the quality of life3,4. 
Uniquely, early glottic cancers (T1-T2N0) are associated with very low rates of cervical lymph node metastases 
(<3%)5. Unlike cancers in other sites of the head and neck, conventional RT is still widely used for early glottic 
cancers because the RT fields are relatively simple and only the larynx is treated without elective cervical lymph 
node irradiation6.
Conventional RT has yielded high cure rates for T1/T2 glottic cancer; however, patients receiving neck irra-
diation can experience acute toxicity such as radiation dermatitis, sore throat, and laryngeal edema5, as well as 
late toxicity such as carotid artery stenosis and an increased risk of stroke7,8. Recent attempts to utilize IMRT for 
early glottic cancer include carotid artery sparing for T1–2N0 cancers9–12 and single vocal cord (VC) irradiation 
for T1aN0 cancers13,14, with the intent to reduce doses to the carotid arteries and normal laryngeal tissues. Since 
2007, we have used 3D conformal radiotherapy (3D-CRT) and IMRT to deliver definitive doses to the involved 
VC(s) while reducing doses to normal laryngeal tissues. We report and compare the outcomes and efficacy of our 
conformal RT protocol for dose de-escalation to the normal larynx with those of the conventional RT technique.
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Material and Methods
Patients. All patients who were diagnosed with stage T1 or T2 squamous cell carcinoma of the glottic larynx, 
had clinically negative cervical lymph nodes (N0), and were treated with definitive RT between January 2004 and 
December 2013 were identified from our institutional database. All patients had undergone evaluations compris-
ing medical history and physical examination, including indirect or flexible fiberoptic laryngoscopy, as well as 
staging computed tomography (CT) of the neck to rule out cervical lymph node involvement and extra-glottic 
spread. All suspicious lesions were biopsied, and slides were reviewed by head and neck pathology expert at our 
institution. Patients were divided into 2 groups according to RT technique: conventional RT (2DRT group) versus 
conformal RT with dose-reduction to the uninvolved larynx (CRT group). The study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki, as revised in 1983, and was approved by the Institutional 
Review Board, Yonsei University Gangnam Severance Hospital (3-2016-0217), with a waiver of informed consent. 
This was a retrospective study for which all data were kept anonymous.
Radiation techniques. All patients received RT alone to the larynx without elective cervical lymph node 
irradiation. All patients underwent CT-based simulation with a 0.15–0.3 cm slice thickness following immo-
bilization with a thermoplastic head and neck mask. For the 2DRT group, the laryngeal box was treated using 
parallel-opposed lateral fields. The borders were the top of the thyroid cartilage superiorly, the bottom of the 
cricoid inferiorly, 1-cm skin flash anteriorly, and 2-cm margin or anterior edge of the vertebral body posteriorly. 
The field size was typically 5 cm × 5 cm for T1N0 and 6 cm × 6 cm for T2N0 cases, with an extension to include the 
first tracheal ring (Fig. 1A). Patients who received CRT were treated with either a sequential boost using the 3D 
conformal RT (3D-CRT) technique or simultaneous-integrated boost using intensity-modulated RT (SIB-IMRT). 
The clinical target volume (CTV)1, which was equal to the gross tumor volume (GTV), encompassed all suspi-
cious lesions identified from laryngoscopy and imaging studies; a 0.3-cm margin was added to define the plan-
ning target volume (PTV)1. CTV2 encompassed the laryngeal box and used the same borders described for 
2DRT; a 0.5–1.0-cm margin was added to define PTV2. The sequential boost technique involved initial treatment 
with parallel-opposed lateral fields, as in 2DRT, and a cone-down to the PTV1 using 2 or 3 co-planar beams 
(Fig. 1B). Helical tomotherapy (Accuray, Madison, WI, USA) was used for SIB-IMRT (Fig. 1C). All plans were 
normalized so that ≥95% of the PTV received 100% of the prescription dose. Dose constraints included limiting 
the maximum dose in the PTV to 105% of the prescription and a soft constraint limiting the mean carotid artery 
dose to 30 Gy. Coverage was prioritized over carotid artery dose. The spinal cord dose was limited to 45 Gy at any 
point.
Follow-up and statistical methods. Generally, patients were followed every 3 months for the first 2 
years, every 6 months up to 5 years after radiotherapy and yearly thereafter. All failures were pathologically con-
firmed. Patients underwent voice assessments and laryngeal stroboscopic examinations. Voice quality assess-
ments included aerodynamic measures and acoustic analyses15. Acute toxicity was evaluated using the Common 
Terminology Criteria for Adverse Events, version 416.
The 2 treatment groups were compared using chi-square tests to detect differences in proportions. Survival 
was calculated from the date of tissue diagnosis until death or the most recent follow-up date. Survival time was 
analyzed using the Kaplan–Meier method, and the log-rank test was used for the univariate analysis. The Cox pro-
portional hazards model was used to assess independent predictors of survival. Preoperative and postoperative 
results for each voice parameter were statistically compared using a paired t-test. SPSS 20.0 software for Windows 
(SPSS, Chicago, IL, USA) was used for these analyses, and statistical significance was defined as a p-value < 0.05.
Results
Patient characteristics. A total of 86 consecutively treated patients were reviewed. After excluding 
3 patients treated with re-irradiation and 3 patients with synchronous double primary cancers, 80 patients 
were eligible for analysis. Among these 80 patients, 38 belonged to the 2DRT group and 42 to the CRT group 
(Supplementary Fig. 1). The median age was 62 years (range: 39–90 years), and most of the patients were men 
(96.2%) and mostly presented with T1–stage disease (56.3%); 30% of patients had anterior commissure involve-
ment. The patient characteristics were well-balanced between the groups, except for a higher proportion of 
patients with a smoking-free interval ≥10 years in the CRT group (p = 0.015) (Table 1). Among patients in the 
2DRT group, the laryngeal box was treated with a median equivalent dose in 2 Gy fractions (EQD2) of 66 Gy 
(range: 60–71 Gy). Among these patients, 19 (50%) underwent adaptive planning using a posterior pharyngeal 
block at a median dose of 50 Gy (range: 36–54 Gy) (Fig. 1A). In the CRT group, 20 patients received a sequential 
boost using 3D-CRT (Fig. 1B), and 22 patients received SIB-IMRT (Fig. 1C). Median EQD2s of 66.6 Gy (range: 
64.3–68.9 Gy) to PTV1 and 52.2 Gy (range: 36.8–61 Gy) to PTV2, respectively, were prescribed.
Treatment outcomes. The median follow-up was 71 months (range: 17–141 months; 2DRT, 97 months; 
CRT, 65 months). Seven patients experienced treatment failures. Two local, 1 local and regional, and 1 synchro-
nous local, regional, and distant failure were reported in the 2DRT group; 2 local and 1 regional failures were 
reported in the CRT group. A detailed assessment of the failure sites is shown in Table 2. Among the 6 patients 
who experienced local failures, 1 had been treated with 3D-CRT with a sequential boost to a T2 tumor involving 
the entire right VC and had experienced recurrence in the contralateral true VC at 31 months after treatment. The 
5-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates for the 2DRT vs. CRT 
groups were 88.1% vs. 95.1% (p = 0.405) (Fig. 2A), 88.1% vs. 86.1% (p = 0.266) (Fig. 2B), and 94.7% vs. 90.7% 
(p = 0.102), respectively. In the CRT group, 3D-CRT with a sequential boost (n = 20) yielded 5-year LC, PFS, and 
OS rates of 95.0%, 80.0%, and 90.0%, respectively, and these values did not significantly differ from those of other 
RT modalities.
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Prognostic factor analysis. Age (≤60 vs. >60 years), T stage (Tis/T1 vs. T2), anterior commissure involve-
ment, smoking-free interval (≥10 vs. <10 years), EQD2 (≥66.6 vs. <66.6 Gy), and RT technique (CRT vs. 2DRT) 
were included in the univariate analysis; of these, only a smoking-free interval <10 years associated significantly 
with decreased LC (p = 0.041). We were unable to analyze the association between the smoking-free interval and 
LC rate in a multivariate analysis because none of the patients with a smoking-free interval ≥10 years experienced 
a recurrence or was censored (Table 3).
Toxicity and voice quality preservation. The incidence of radiation-induced acute toxicity according to 
treatment groups is summarized in Table 4. Rates of grade 2 and 3 pharyngitis were 52.6% and 5.3% for 2DRT vs. 
35.7% and 2.4% for CRT (p = 0.121). Rates of grade 2 and 3 dermatitis were 42.1% and 2.6% for 2DRT vs. 35.7% 
and 0% for CRT (p = 0.013). In the CRT group, rates of grade 2 and 3 pharyngitis were 35.0% and 0% for 3D-CRT 
Figure 1. Radiotherapy (RT) plans for typical patients: conventional RT (2DRT) (A), 3-dimensional conformal 
RT (3D-CRT) with sequential boost (B), and simultaneous-integrated boost using intensity-modulated RT 
(SIB-IMRT) (C).
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vs. 36.4% and 4.5% for IMRT (p = 0.127), and rates of grade 2 and 3 dermatitis were 50.0% and 0% for 3DCRT vs. 
22.7% and 0% for IMRT (p = 0.001). Both pre-RT and delayed post-RT (>6 months) voice quality assessments 
were available for 40 patients (n = 14 for 2DRT and 26 for CRT), and voice qualities were compared between 
the 2 time points. The maximum phonation time (MPT) increased from 12.1 ± 6.1 seconds to 13.9 ± 9.0 sec-
onds for all patients (p = 0.176), from 12.1 ± 7.1 seconds to 14.0 ± 6.6 seconds for the 2DRT group (p = 0.375), 
and from 12.0 ± 5.5 to 13.8 ± 10.1 seconds for the CRT group (p = 0.313). The average fundamental frequency 
(F0) decreased from 142.7 ± 35.0 Hz to 124.7 ± 25.9 Hz for all patients (p = 0.005), from 150.6 ± 40.3 Hz to 
121.9 ± 30.2 Hz for 2DRT (p = 0.039), and from 138.5 ± 31.9 Hz to 126.1 ± 23.7 Hz for CRT (p = 0.058) (Table 5). 
In the CRT group, MPT increased from 13.5 ± 5.9 to 16.3 ± 12.8 seconds for the 3D-CRT group (p = 0.378) and 
from 10.8 ± 5.1 to 11.7 ± 7.0 seconds for the IMRT group (p = 0.654), and F0 decreased from 138.7 ± 32.7 Hz to 
132.6 ± 29.9 Hz for 3D-CRT (p = 0.252) and from 138.3 ± 32.4 Hz to 120.6 ± 16.0 Hz for IMRT (p = 0.123).
Discussion
Previous studies of conventional RT have reported 5-year LC rates of 84–95% for T1a and 50–85% for T2 glottic 
cancers17. In malignancies associated with long-term survival, such as early glottic cancer, the greatest opportunity 
for therapeutic advancement lies in the prevention of toxicity while maintaining excellent oncologic outcomes. 
The current study included patients with Tis (9%), T1 (56%), and T2 (25%) disease, and achieved 5-year LC and 
OS rates of 91.3% and 93.1%, respectively. These results were comparable to those of previous reports17. Attempts 
Characteristics Total (n = 80) 2DRT (n = 38) CRT (n = 42) P value
Age 0.469
 ≤60 years 33 (41.3%) 15 (39.5%) 18 (42.9%)
 >60 years 47 (58.7%) 23 (60.5%) 24 (57.1%)
Sex 0.538
 Male 77 (96.2%) 37 (97.4%) 40 (95.2%)
 Female 3 (3.8%) 1 (2.6%) 2 (4.8%)
T staging 0.487
 Tis 7 (8.8%) 3 (7.9%) 4 (9.5%)
 T1a 47 (58.7%) 24 (63.2%) 23 (54.7%)
 T1b 6 (7.5%) 4 (10.5%) 2 (4.8%)
 T2 20 (25.0%) 7 (18.4%) 13 (31.0%)
Smoking-free 0.015
 ≥10 years 32 (40.0%) 10 (26.3%) 22 (52.4%%)
 <10 year 48 (60.0%) 28 (73.7%) 20 (47.6%)
Ant. Commissure 0.331
 Not involved 56 (70.0%) 28 (73.7%) 28 (66.7%)
 Involved 24 (30.0%) 10 (26.3%) 14 (33.3%)
Diagnosis 0.299
 Biopsy 58 (72.5%) 26 (68.4%) 32 (76.2%)
 LMS 22 (27.5%) 12 (31.6%) 10 (23.8%)
Total EQD2 0.282
 ≥66.6 Gy 50 (62.5%) 22 (57.9%) 28 (66.7%)
 <66.6 Gy 30 (37.5%) 16 (42.1%) 14 (33.3%)
Table 1. Patient Characteristics. Abbreviations: LMS = laryngeal microscopic surgery; EQD2 = equivalent dose 
in 2 Gy fractions.
Age/Sex Stage Site AC Smoke free RT EQD2 (Gy) Fail site LF site (recur stage) PFS (m)
85/M T1a/Rt A-M no current 2D 64.0 L Ipsi ant-VC (rT1a) 6.1
61/M T1a/Lt Entire no 3yrs 2D 64.0 L Ipsi entire VC (rT1a) 53.0
48/M Tis/Lt A1/3 yes 4yrs 2D 64.0 L/R/D Ipsi thyroid (rT4a) 46.7
69/M T1b/Bl Entire no 7yrs 2D 66.0 L/R Ipsi VC/thyroid (rT4a) 11.9
60/M T2/Rt Entire yes current 3DCRT 68.9 L Cont mid-VC (rT1a) 30.9
50/M T2/Rt A-M no 20yrs 3DCRT 68.9 R None 12.7
62/M T2/Rt P1/3 no current IMRT 68.9 L/R/D Ipsi post-VC (rT2) 10.8
Table 2. Assessment of failure sites. Abbreviations: Rt = right; Lt = left; Bl = bilateral; A-M = anterior to middle 
cord; A1/3 = anterior 1/3; P1/3 = posterior 1/3; AC = anterior commissure involvement; EQD2 = equivalent 
dose in 2 Gy fractions; L = local; R = regional; L/R = local and regional; L/R/D = local and regional and 
distant; LF = local failure; Ipsi = ipsilateral; VC = vocal cord; Cont = contralateral; PFS = disease-free survival; 
m = months.
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have been made to reduce normal tissue toxicity during the delivery of definitive RT for early glottic cancers. 
Several studies have demonstrated the role of IMRT in reducing the doses delivered to the carotid arteries9,10,12 a 
nd soft tissues of the neck18, although the long-term benefits of these efforts remain to be established. Apparent 
Figure 2. Comparison of treatment outcomes between the conventional radiotherapy (2DRT) and conformal 
RT (CRT) groups: local control rates (A) and progression-free survival (B).
Variables
No patients 
(%)
Univariate Multivariate
5-yr LFFS 
(%) 95%CI P RR 95%CI P
Age
  ≤60 33 (41.3) 92.7 83–103 0.640
  >60 47 (58.7) 90.1 81–100
T stage
  Tis/T1 60 (75.0) 91.6 84–100 0.651
  T2 20 (25.0) 89.7 76–103
Ant commissure
  Not involved 56 (70.0) 91.9 84–100 0.851
  Involved 24 (30.0) 89.3 75–104
Smoking-free
  ≥10 years 32 (40.0) 100 n/a 0.041 n/a n/a n/a
  <10 years 48 (60.0) 85.6 75–96
EQD2
  ≥66.6 Gy 48 (60.0) 94.0 87–101 0.335 0.506 0.10–2.60 0.415
  <66.6 Gy 32 (40.0) 79.8 57–102
RT technique
  CRT 42 (52.5) 95.1 88–102 0.405 1.156 0.21–6.47 0.869
  2DRT 38 (47.5) 88.1 77–99
Table 3. Prognostic factors affecting local control rate. Abbreviations: CI = confidence interval; RR = relative 
risk; EQD2 = equivalent dose in 2 Gy fractions; CRT = conformal radiotherapy; 2DRT = conventional 
radiotherapy.
Total (n = 80) 2DRT (n = 38) CRT (n = 42) P value
Pharyngitis Grade 0 4 0 4 (9.5%) 0.121
Grade 1 38 16 (42.1%) 22 (52.4%)
Grade 2 35 20 (52.6%) 15 (35.7%)
Grade 3 3 2 (5.3%) 1 (2.4%)
Dermatitis Grade 0 21 4 (10.5%) 17 (40.5%) 0.013
Grade 1 27 17 (44.7%) 10 (23.8%)
Grade 2 31 16 (42.1%) 15 (35.7%)
Grade 3 1 1 (2.6%) 0
Table 4. Acute toxicity.
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concerns regarding increased local failures emerge when only a single VC is irradiated, although most stud-
ies consider selected patients with T1a cancers to be eligible for such treatment. For example, Levendag et al. 
reported a 5-year LC rate of 93% after single VC irradiation in 164 patients with T1a cancers14. Despite the very 
limited clinical experience, single VC irradiation seems feasible in selected T1a patients.
In the current study, the treatment scheme applied to the CRT group was somewhat unique in that the 
involved VC received the full dose of 67 Gy EQD2, whereas the remainder of the larynx received a reduced dose 
of 52 Gy EQD2 with the intent to reduce toxicity to the normal larynx while maintaining LC. The 5-year LC rates 
were 95.1% for the CRT group and 88.1% for the 2DRT group, and demonstrate the efficacy of our CRT proto-
col. Unexpectedly, the LC rate with 2DRT was lower than with CRT. We demonstrated a significant association 
between a longer smoking-free interval and LC, and noted that the CRT group had a significantly higher pro-
portion of patients with a smoking-free interval ≥10 years (Table 1); accordingly, the higher LC rate in the CRT 
group might be attributable to this inter-group difference in the smoking-free interval.
A recurrence in the contralateral true VC was reported in 1 patient in the CRT group. This patient exhibited 
strong risk factors for recurrence, including T2 stage disease, a tumor involving the entire VC and anterior com-
missure, and a status as a current smoker at the time of diagnosis. Interestingly, 2DRT resulted in local failures 
only in patients with Tis/T1 glottic cancers, whereas CRT resulted in local failures only in patients with T2 glottic 
cancers (Table 2). In the American Joint Committee on Cancer staging manual, 7th edition19, a designation of 
T2 glottic cancer requires extension of the disease to the supraglottis and/or subglottis; however, such tumor 
extension is not readily detectable on CT images, thus increasing the difficulty of accurate target delineation. 
Possibly, our current definition of PTV1 as gross disease with a 3-mm margin might not have provided adequate 
tumor coverage in T2 cases. A study conducted at Princess Margaret Hospital compared conventional RT (n = 48) 
and normal tissue-sparing IMRT (n = 50) exclusively for T2 glottic cancer. For IMRT, CTV60 was defined as a 
0.5–1.0 cm expansion on the GTV, and CTV50 was variably defined to include a further expansion of 0.5–2.0 cm 
on the CTV60. In 17 of the 50 IMRT cases, the CTV50 was expanded to include the whole larynx; however, the 
3-year local recurrence rate was higher when compared to that of conventional RT (32% vs. 20%, p = 0.54). In 
all cases, the local relapse sites included the supraglottis 64% and subglottis 88%20. Based on these observations, 
we have modified our scheme of target delineation for T2 glottic cancer as follows: PTV1 is defined by adding 
0.3-cm margins around all suspicious lesions (GTV) identified via laryngoscopy and imaging studies; PTV2 is 
equal to CTV and encompasses the entire larynx, including the both the anterior and posterior commissures and 
arytenoids; and PTV3 is defined as a 0.5–1-cm expansion of the PTV2. The prescribed doses to PTV1, PTV2, and 
PTV3 are 65.25 Gy, 58.0 Gy, and 49.3 Gy delivered over 29 fractions, respectively.
Although conventional RT provides high rates of LC for early glottic cancer, there remains room for improve-
ment in terms of toxicity reduction. The incidence rates of grade 2 and 3 dermatitis were 42% and 1% with 2DRT 
vs. 36% and 0% with CRT (p = 0.013). There is a concern that IMRT increases the dose to the skin in head and 
neck cancer patients6. In our protocol, however, the skin is intentionally spared from target delineation unless 
the anterior commissure is involved, and the resultant incidence of dermatitis supports the efficacy of our CRT 
protocol with regard to reducing acute skin toxicity. Even in cases of grade 2 dermatitis, the involved skin area was 
limited to that adjacent to the anterior commissure, thus reducing discomfort and improving patient compliance 
with treatment. Despite the significant reduction in dermatitis, CRT did not result in significant reduction in the 
rates of grade 2 and 3 pharyngitis when compared with 2DRT (p = 0.121). At our institution, if the disease is well 
localized in the anterior half of the VC, a posterior pharyngeal block is often employed during 2DRT delivery to 
reduce the occurrence of odynophagia. In the current study, 50% of patients in the 2DRT group underwent treat-
ment with adaptive plans for pharyngeal sparing, thus reducing the risk of pharyngitis.
Preservation of voice quality is a key factor when deciding treatment options for early glottic cancer. Previous 
studies have compared the functional outcomes, including voice quality, of transoral laser surgery and conven-
tional RT21–23; however, to our knowledge, no studies have compared the functional outcomes of IMRT and con-
ventional RT modalities. Unfortunately, routine assessments of voice quality before and after radiotherapy were 
not implemented at our institution until 2008; as a result, these data are only available for 50% of the total cohort, 
with an imbalance in data availability between the 2 treatment groups. Although the maximum phonation time 
(MPH) improved after both 2DRT and CRT, these improvements were not significant. The average fundamental 
frequency (F0) also improved after both treatment modalities; this difference was statistically significant in the 
2DRT group (p = 0.039) and indicated a trend of improvement in the CRT group (p = 0.058). Although many 
confounding factors influence the voice quality beyond 6 months after RT, the long-term changes in voice quality 
in the treatment groups appeared comparable. A further report will follow, as the voice quality data are being 
accumulated using standardized assessment procedures.
Pre-RT Post-RT ≥ 6 mo P
MPT (sec)
All (n = 40/80) 12.1 ± 6.1 13.9 ± 9.0 0.176
2DRT (n = 14/38) 12.1 ± 7.1 14.0 ± 6.6 0.375
CRT (n = 26/42) 12.0 ± 5.5 13.8 ± 10.1 0.313
F0 (Hz)
All (n = 40/80) 142.7 ± 35.0 124.7 ± 25.9 0.005
2DRT (n = 14/38) 150.6 ± 40.3 121.9 ± 30.2 0.039
CRT (n = 26/42) 138.5 ± 31.9 126.1 ± 23.7 0.058
Table 5. Changes in maximum phonation time and fundamental frequency (n = 40/80). Abbreviations: 
MPT = maximum phonation time; F0 = average fundamental frequency.
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This study has several limitations. This was a retrospective study, and thus confounding factors between the 
CRT and 2DRT groups might have affected the results. Indeed, the CRT group had a higher proportion of patients 
with a smoking-free interval ≥10 years, and therefore had a higher (although not statistically significant) LC rate 
when compared with the 2DRT group. Both groups, however, exhibited LC rates comparable to those in previous 
reports, thus demonstrating the efficacy of our CRT protocol. The CRT group comprised patients treated with 2 
different RT modalities: 3D-CRT with sequential boost and SIB-IMRT. The Korean National Health Insurance 
began reimbursing costs related to IMRT for head and neck cancer in 2011, and since then, we have employed 
SIB-IMRT for all early glottic cancer cases. Although the numbers were too small for statistical comparison, the 
treatment outcomes of 3D-CRT (95.0% LC and 90.0% OS) were comparable to those of other RT modalities in the 
current study. Furthermore, the retrospective nature meant that toxicity assessments were not performed at reg-
ular intervals, which somewhat reduced the validity of our toxicity comparison between the 2 treatment groups. 
Nevertheless, several studies have previously shown the dosimetric advantages of IMRT in terms of reducing the 
doses to laryngeal soft tissues and carotid arteries. We are currently following up IMRT-treated patients in the 
context of a prospective observational study, and an additional report will follow.
Conclusion
CRT can be used to effectively de-escalate the dose to the normal larynx in the context of early glottic cancer 
treatment, resulting in reduced toxicity while maintaining oncologic outcomes and voice quality. The use of IMRT 
for maintaining effective tumor control of T2 glottic cancer requires attention to the extent of the disease in target 
delineation.
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